Acceleron Pharma (Acceleron Pharma) Total Liabilities : $69.7 Mil (As of Sep. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Total Liabilities?

Acceleron Pharma's Total Liabilities for the quarter that ended in Sep. 2021 was $69.7 Mil.

Acceleron Pharma's quarterly Total Liabilities increased from Mar. 2021 ($64.96 Mil) to Jun. 2021 ($73.02 Mil) but then declined from Jun. 2021 ($73.02 Mil) to Sep. 2021 ($69.70 Mil).

Acceleron Pharma's annual Total Liabilities increased from Dec. 2018 ($22.78 Mil) to Dec. 2019 ($55.43 Mil) and increased from Dec. 2019 ($55.43 Mil) to Dec. 2020 ($77.23 Mil).

Acceleron Pharma Total Liabilities Historical Data

The historical data trend for Acceleron Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma Total Liabilities Chart

Acceleron Pharma Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Liabilities

Get a 7-Day Free Trial

22.05

23.96

22.78

55.43

77.23

Acceleron Pharma Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Total Liabilities	Get a 7-Day Free Trial															52.63	77.23	64.96	73.02	69.70

Acceleron Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Acceleron Pharma's Total Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	60.163	+	(17.067	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	77.2

Total Liabilities	=	Total Assets (A: Dec. 2020 )	-	Total Equity (A: Dec. 2020 )
	=	932.337	-	855.107
	=	77.2

Acceleron Pharma's Total Liabilities for the quarter that ended in Sep. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57.371	+	(11.951	+	0.37299999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	69.7

Total Liabilities	=	Total Assets (Q: Sep. 2021 )	-	Total Equity (Q: Sep. 2021 )
	=	787.848	-	718.153
	=	69.7

Acceleron Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Acceleron Pharma (Acceleron Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Sidney Street, Cambridge, MA, USA, 02139

Website

http://www.acceleronpharma.com

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Executives

Sujay Kango	officer: EVP, Chief Commercial Officer	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin	officer: SVP, CFO and Treasurer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness	officer: SVP, General Counsel and Sec.	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable	director, officer: CEO and President	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co	10 percent owner	430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George	director	CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik	director	C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139